IL2 and chronic kidney disease: In this study, we demonstrated that low-dose IL-2 could selectively expand Tregs ex vivo in PBMCs isolated from CKD patients, and expanded Tregs exhibit effective and potent suppressive function against the production of Th1 and Th17 cells.